EP1996937A4 - Genetische packungen und verwendungen davon - Google Patents

Genetische packungen und verwendungen davon

Info

Publication number
EP1996937A4
EP1996937A4 EP07752549A EP07752549A EP1996937A4 EP 1996937 A4 EP1996937 A4 EP 1996937A4 EP 07752549 A EP07752549 A EP 07752549A EP 07752549 A EP07752549 A EP 07752549A EP 1996937 A4 EP1996937 A4 EP 1996937A4
Authority
EP
European Patent Office
Prior art keywords
genetic packages
packages
genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07752549A
Other languages
English (en)
French (fr)
Other versions
EP1996937A2 (de
Inventor
Volker Schellenberger
Willem P Stemmer
Chia-Wei Wang
Michael D Scholle
Mikhail Popkov
Nathaniel C Gordon
Andreas Crameri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amunix Pharmaceuticals Inc
Original Assignee
Amunix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1996937(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/528,927 external-priority patent/US20070191272A1/en
Application filed by Amunix Inc filed Critical Amunix Inc
Publication of EP1996937A2 publication Critical patent/EP1996937A2/de
Publication of EP1996937A4 publication Critical patent/EP1996937A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07752549A 2006-03-06 2007-03-06 Genetische packungen und verwendungen davon Withdrawn EP1996937A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74341006P 2006-03-06 2006-03-06
US74362206P 2006-03-21 2006-03-21
US11/528,927 US20070191272A1 (en) 2005-09-27 2006-09-27 Proteinaceous pharmaceuticals and uses thereof
US11/528,950 US20070212703A1 (en) 2005-09-27 2006-09-27 Proteinaceous pharmaceuticals and uses thereof
PCT/US2007/005857 WO2007103455A2 (en) 2006-03-06 2007-03-06 Genetic packages and uses thereof

Publications (2)

Publication Number Publication Date
EP1996937A2 EP1996937A2 (de) 2008-12-03
EP1996937A4 true EP1996937A4 (de) 2009-04-08

Family

ID=38475542

Family Applications (3)

Application Number Title Priority Date Filing Date
EP07752549A Withdrawn EP1996937A4 (de) 2006-03-06 2007-03-06 Genetische packungen und verwendungen davon
EP20140189047 Ceased EP2863222A1 (de) 2006-03-06 2007-03-06 Unstrukturierte rekombinante Polymere und Verwendungen davon
EP07752636.6A Active EP1996220B2 (de) 2005-09-27 2007-03-06 Unstrukturierte rekombinante polymere und verwendungen davon

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP20140189047 Ceased EP2863222A1 (de) 2006-03-06 2007-03-06 Unstrukturierte rekombinante Polymere und Verwendungen davon
EP07752636.6A Active EP1996220B2 (de) 2005-09-27 2007-03-06 Unstrukturierte rekombinante polymere und verwendungen davon

Country Status (6)

Country Link
EP (3) EP1996937A4 (de)
AU (2) AU2007223888A1 (de)
CA (1) CA2644712C (de)
DK (1) DK2402754T4 (de)
SI (1) SI2402754T2 (de)
WO (2) WO2007103515A2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903036B2 (ja) 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1971355B1 (de) 2005-12-20 2020-03-11 Duke University Verfahren und zusammensetzungen zur abgabe von wirkstoffen mit verbesserten pharmakologischen eigenschaften
EP1996937A4 (de) 2006-03-06 2009-04-08 Amunix Inc Genetische packungen und verwendungen davon
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
DK2369005T3 (da) 2007-06-21 2013-06-24 Univ Muenchen Tech Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro
AU2008287340A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
AU2015218510B2 (en) * 2009-02-03 2016-11-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
AU2014206217B2 (en) * 2009-02-03 2015-09-17 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
JP2012524030A (ja) 2009-04-20 2012-10-11 アンジオケム インコーポレーテッド Ａｎｇｉｏｐｅｐ−２アナログにコンジュゲート化した抗癌剤を用いた卵巣癌の治療
CN106916229A (zh) * 2009-06-08 2017-07-04 阿穆尼克斯运营公司 生长激素多肽及其制备和使用方法
NZ596778A (en) 2009-06-08 2013-11-29 Amunix Operating Inc Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
KR101813727B1 (ko) * 2009-06-08 2018-01-02 아뮤닉스 오퍼레이팅 인코포레이티드 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
AU2010290077C1 (en) * 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
WO2011060583A1 (zh) * 2009-11-19 2011-05-26 浙江大学 非天然的胶原样蛋白及其应用
AU2010325787B2 (en) 2009-12-06 2016-05-12 Bioverativ Therapeutics Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
EP3372617B1 (de) * 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsproteinarzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
EP2571510B1 (de) 2010-05-21 2018-08-08 XL-protein GmbH Biosynthetische Prolin-/Alanin-Random-Coil-Polypeptide
ES2486321T3 (es) 2010-06-18 2014-08-18 Xiberscience Gmbh Péptidos como agentes activos para estabilizar barreras biológicas
NZ605348A (en) 2010-07-09 2015-01-30 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
EP3513804B1 (de) 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Chimäre und hybride faktor-viii-polypeptide und verfahren zur verwendung davon
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
WO2013106787A1 (en) * 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
WO2013130684A1 (en) 2012-02-27 2013-09-06 Amunix Operating Inc. Xten-folate conjugate compositions and methods of making same
EP2846836B1 (de) 2012-05-07 2019-08-14 Allergan, Inc. Verfahren zur behandlung von amd bei gegen eine anti-vegf-therapie unempfindlichen patienten
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
CA2877584A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
KR102403545B1 (ko) 2012-07-11 2022-05-30 바이오버라티브 테라퓨틱스 인크. Xten 및 폰 빌레브란트 인자 단백질과의 viii 인자 복합체 및 이의 용도
US20150252345A1 (en) 2012-09-25 2015-09-10 Biogen Idec Ma Inc. Methods of Using FIX Polypeptides
EP2738180A1 (de) 2012-11-30 2014-06-04 Molecular Partners AG Bindeproteine mit mindestens zwei Bindedomänen gegen HER2
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
EP3033097B1 (de) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Faktor viii-xten fusionen sowie ihre verwendungen.
CA2927012A1 (en) 2013-11-05 2015-05-14 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
CN117106095A (zh) 2014-01-10 2023-11-24 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
HUE048076T2 (hu) 2014-06-18 2020-07-28 Albert Einstein College Of Medicine Syntac polipeptidek és alkalmazásaik
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
EP3220961B1 (de) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutische vitamin-d-konjugate
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
KR20220109488A (ko) 2015-04-02 2022-08-04 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
EP3303380B1 (de) 2015-06-02 2020-01-15 Novo Nordisk A/S Insuline mit polaren rekombinanten erweiterungen
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
CA2992306A1 (en) 2015-08-28 2017-03-09 Amunix Operating Inc. Chimeric polypeptide assembly and methods of making and using the same
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
EP3458096A4 (de) 2016-05-18 2019-11-27 Cue Biopharma, Inc. T-zell-modulierende multimere polypeptide und verfahren zur verwendung davon
IL262606B2 (en) 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
SI3558339T1 (sl) 2016-12-22 2024-05-31 Cue Biopharma, Inc. Celico T modulirajoči multimerni polipeptidi in postopki njihove uporabe
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
MA49339A (fr) 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
EP3737689A4 (de) 2018-01-09 2021-12-01 Cue Biopharma, Inc. Multimere t-zell-modulierende polypeptide und verfahren zur verwendung davon
WO2019201855A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Lysosomal fusion protein
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
JP7549579B2 (ja) 2018-12-19 2024-09-11 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節ポリペプチド及びその使用方法
JP2022522405A (ja) 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
EP4222176A4 (de) 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. Polypeptidkonjugate und verfahren zur verwendung
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
EP4259199A1 (de) 2020-12-11 2023-10-18 Friedrich Miescher Institute for Biomedical Research Hdac6-bindende proteine und deren antivirale verwendung
CN115083016A (zh) * 2022-06-09 2022-09-20 广州紫为云科技有限公司 一种基于单目摄像机的面向小目标手部隔空交互方法与装置

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD257197A1 (de) † 1987-01-28 1988-06-08 Univ Dresden Tech Verfahren zur herstellung von immobilisierten, in ihrer biologischen aktivitaet stabilisierten und in ihren pharmakologischen eigenschaften modifizierten insulinpraeparationen
FR2647677B1 (fr) * 1989-05-31 1991-09-27 Roussel Uclaf Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines
AU662508B2 (en) † 1990-12-13 1995-09-07 Pharmacia & Upjohn Company Fusion polypeptides
US5833911A (en) † 1995-05-31 1998-11-10 Johnson & Johnson Medical, Inc. Method for forming a glove using a folded glove form
WO1998022577A1 (en) † 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
US20050260605A1 (en) * 1998-02-11 2005-11-24 Maxygen, Inc. Targeting of genetic vaccine vectors
EP1054973A1 (de) * 1998-02-11 2000-11-29 Maxygen, Inc. Antigen bibliothek immunisierung
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20030049689A1 (en) * 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
PE20020908A1 (es) † 2001-03-21 2002-10-26 Cell Therapeutics Inc Produccion recombinante de polimeros polianionicos y uso de de los mismos
EP1841787A2 (de) * 2005-01-25 2007-10-10 Cell Therapeutics, Inc. Biologisch-active proteinkonjugate mit modifizierten in-vivo halbwertzeit
EP1971355B1 (de) † 2005-12-20 2020-03-11 Duke University Verfahren und zusammensetzungen zur abgabe von wirkstoffen mit verbesserten pharmakologischen eigenschaften
EP1996937A4 (de) 2006-03-06 2009-04-08 Amunix Inc Genetische packungen und verwendungen davon
WO2008049711A1 (en) † 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BULAJ GRZEGORZ ET AL: "Efficient oxidative folding of conotoxins and the radiation of venomous cone snails.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. Supplement 2, 25 November 2003 (2003-11-25), pages 14562 - 14568, XP002515375, ISSN: 0027-8424 *
CHEN X J ET AL: "Site-directed mutations in a highly conserved region of Bacillus thuringiensis delta-endotoxin affect inhibition of short circuit current across Bombyx mori midguts.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1 OCT 1993, vol. 90, no. 19, 1 October 1993 (1993-10-01), pages 9041 - 9045, XP002515378, ISSN: 0027-8424 *
GOMEZ-DUARTE O G ET AL: "Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 13, no. 16, 1 November 1995 (1995-11-01), pages 1596 - 1602, XP004057422, ISSN: 0264-410X *
PI C ET AL: "Analysis of expressed sequence tags from the venom ducts of Conus striatus: focusing on the expression profile of conotoxins", BIOCHIMIE, MASSON, PARIS, FR, vol. 88, no. 2, 1 February 2006 (2006-02-01), pages 131 - 140, XP025066514, ISSN: 0300-9084, [retrieved on 20060201] *

Also Published As

Publication number Publication date
EP1996220A2 (de) 2008-12-03
WO2007103515A3 (en) 2008-04-03
EP2863222A1 (de) 2015-04-22
EP1996937A2 (de) 2008-12-03
EP1996220A4 (de) 2009-04-29
DK2402754T4 (da) 2023-08-28
AU2007223888A1 (en) 2007-09-13
CA2644712A1 (en) 2007-09-13
EP1996220B1 (de) 2013-05-08
WO2007103455A2 (en) 2007-09-13
AU2007223855A1 (en) 2007-09-13
AU2007223855B2 (en) 2013-05-16
WO2007103455A3 (en) 2007-11-29
SI2402754T1 (sl) 2015-02-27
CA2644712C (en) 2016-09-13
SI2402754T2 (sl) 2023-09-29
WO2007103515A2 (en) 2007-09-13
EP1996220B2 (de) 2023-08-16
DK2402754T3 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
EP1996937A4 (de) Genetische packungen und verwendungen davon
ZA200810323B (en) Fkbp-l and uses thereof
PL2064327T3 (pl) Dbait i ich zastosowania
ZA200810311B (en) Anti-NKG2A antibodies and uses thereof
ZA200902823B (en) Oligoribonucleotides and uses thereof
IL196397A0 (en) Prlr-specific antibody and uses thereof
AU313874S (en) Package
IL194751A0 (en) Drugs and uses
GB0621160D0 (en) Compounds and uses thereof
HK1133552A1 (en) Carboranylporphyrins and uses thereof
IL196861A0 (en) Antibodies against ccr5 and uses thereof
IL195525A0 (en) Replikin peptides and uses thereof
IL193469A0 (en) Novel lipases and uses thereof
EP2124908A4 (de) Verbindungen und ihre verwendung
GB0604187D0 (en) Peptide and uses thereof
EP2120563A4 (de) Verbindungen und ihre verwendungen
EP2099459A4 (de) Verbindungen und ihre verwendungen
GB0603717D0 (en) Electricity-generate and store
PL2032708T3 (pl) Rekombinowane nowirabdowirusy i ich zastosowania
IL192800A0 (en) Fgf2-binding peptides and uses thereof
EP2120957A4 (de) Verbindungen und ihre verwendungen
ZA200807233B (en) Novel lipases and uses thereof
GB0621665D0 (en) Blogmail and podmail
GB2444960B (en) Combined pseudoscope and hyperscope
GB0615557D0 (en) Compounds and Uses Thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081006

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090305

17Q First examination report despatched

Effective date: 20090717

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMUNIX OPERATING INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110421